Medical University of South Carolina

MEDICA
MUSC Theses and Dissertations
2012

Biochemical Links between Hormonal Mediators of Psychological
Stress and the Expression of MUC1 in Prostate Cancer Cells
Kristina Andrijauskaite
Medical University of South Carolina

Follow this and additional works at: https://medica-musc.researchcommons.org/theses

Recommended Citation
Andrijauskaite, Kristina, "Biochemical Links between Hormonal Mediators of Psychological Stress and the
Expression of MUC1 in Prostate Cancer Cells" (2012). MUSC Theses and Dissertations. 36.
https://medica-musc.researchcommons.org/theses/36

This Thesis is brought to you for free and open access by MEDICA. It has been accepted for inclusion in MUSC
Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact
medica@musc.edu.

Biochemical Links between Hormonal Mediators of Psychological Stress and the
Expression ofMUCl in Prostate Cancer Cells

by

Kristina Andrijauskaite

A Thesis submitted to the faculty of the Medical University of South Carolina in partial
fulfillment of the requirements for the degree of
Master of Science in the College of Graduate Studies

Department of Biochemistry and Molecular Biology

2012

Approved by:
Chairman, Advisory Committee

/'

~::2L-~

-<

t/ /
. ". .

1-

~~:
_>,?-.....,--~

Daniel J. Feman(fes~ PhD ~ D.Se.

Antony j. Alber ,
Katherine R. Sterb

TABLE OF CONTENTS

ABSTRACT ............................................................................................ ii
ACKNOWLEDGEMENTS ........................................................................ .iv
LIST OF FIGURES .................................................................................... v
LIST OF ABBREVIATIONS ...................................................................... vii

CHAPTERS
1.

INTRODUCTION TO THE RESEARCH ............................

II.

LITERATURE REVIEW ............... 0.' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8

III.

MATERIALS AND METHODS ................................................. 21

IV.

RESULTS ....................................

V.

CONCLUSIONS ................................................................. 38

VI.

DISCUSSION ..................................................................... 42

VII.

SIGNIFICANCE .................................................................. 48

VIII.

REFERENCES .................................................................... 71

1

0

0"

•••••••

•••••••••••••••••••••••••••••••••••••

1

29

Abstract
A growing body of scientific evidence has demonstrated that chronic psychological

stress can not only increase the growth and metastasis of tumors through a number of
mechanisms, such as by an increase of VEGF and Bcl-2, but also can decrease the
survival of cancer patients. However, no studies have reported the effect of psychological
stress with respect to the tumor marker MUC 1. Therefore, building upon previous
research, the purpose of the present study was to investigate the effect of the stress
hormones cortisol and norepinephrine on the tumor marker MUC1, which is highly
associated with tumor cell metastasis and is aberrantly glycosylated in most human
epithelial carcinomas. Thus, it has been widely used in clinics as an important prognostic
marker of disease progression and response to treatment. Overexpression of MUel in
prostate cancer has been associated with more aggressive disease and an increased risk of
recurrence.
Using the OU-145 prostate cancer cell line as an experimental model, we sought to
determine whether the glucocorticoid cortisol and the catecholamine norepinephrine
enhanced the expression of MUel at the transcriptional and protein levels, and whether
increased MUCI altered the invasive potential of DV-145 cells. The levels of MUCl
protein expression were assayed by ELISA, flow cytometry, and the colorimetric
bradford assay. The mRNA levels ofMUCl were measured by RT-PCR. In addition, cell
invasiveness and migration were assayed by the matrigel migration assay.
The results indicate that physiologically relevant concentrations of cortisol found in
tumor microenvironment (10

-7

M) enhanced the expression of MUCI by approximately

2-fold after 6 or 10 days of treatment as assayed by ELISA. In addition, flow cytometric
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analyses revealed that DU-145 cells treated for 3 or 6 days with cortisol up-regulated the
cell-surface expression of Muel by approximately 2-fold, whereas a 10 day exposure
up-regulated the expression by 7-fold. Norepinephrine alone did not alter the expression
ofMUCl at any time point in any of the experiments. In addition to these elevated levels
ofMUCl protein., the mRNA levels of MUCI were increased by 6-fold when cells were
treated with cortisol for 6 days and by 4-fold when cells were treated for 10 days, while
norepinephrine had no effect on mRNA levels. In addition, the matrigel migration assay
indicated that cells treated with cortisol for 6-10 days migrated faster through the
membrane as compared to untreated cells.
Together, data generated from this thesis provide novel evidence of a biochemical link
between the glucocorticoid cortisol, a hormonal mediator of psychological stress, and
increased levels of the tumor marker MUC 1. Findings arising from this thesis raise the
possibility that in prostate cancer the interaction of MUe 1 with stress hormones, such as
cortisol may increase the expression of MUel resulting in the observed increase in
disease in psychologically stressed individuals. These novel findings highlight the
necessity for future studies designed to investigate further the relationship between
hormonal mediators of psychological stress and increased levels of MUC 1.
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CHAPTER I
INTRODUCTION TO THE RESEARCH

1. Introduction to hormonal mediators of psychological stress, and the tumor marker,
MUCI.
1.1. Psychological Stress

Despite extensive research on varIOUS aspects of stress, investigators still find it
difficult to achieve a satisfactory definition of this concept (Segerstrom & Miller, 2004).
We adopted the definition of stress based on two perspectives: psychological and
biomedical. According to the National Cancer Institute (NCI), psychological stress refers
to the

~~emotional

and physiological reactions experienced when an individual confronts a

situation in which the demands go beyond the person's coping resources". From the
biomedical perspective, based on the pioneering work of Hans Selye (known as "the
father of stress") and Walter Cannon (a pioneer in modem stress theory) (Mason., 1975).,
stress is defined as "an alteration in the body"s honnonal and neuronal secretions caused
by the central nervous system in response to a perceived threat" and a stressor is viewed

as "a change in an

individual~s

internal or external enviromnent which is perceived by the

organism as threatening" (Strange et al. 2000). In

the~short

term, stress promotes survival

functions of the body by increasing blood pressure, blood sugar levels and promoting
analgesia (Matousek et al. 2010). However, when stress persists over a long period of
time (chronic stress) it is considered to be harmful and may promote a number of diseases
(Kageyama, 2011; Habib et al. 2001; Chrousos & Gold, 1992). Chronis stress could last
for days., months, or years (Antoni et al. 2006; Contrada & Baum., 2010). In acute stress.,
after the stress reaction is removed or ends the hormone levels start,to subside. In chronic
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stress, however, the stress hormone production can be elevated for prolonged periods
(Antoni et al. 2006). From the biochemical point of view, the survival of multicellular
organisms depends on their ability to successfully adapt to their constantly changing
environment. The nervous system and the endocrine system provide intracellular
communication required for this adaptation (Murray et al. 2006). Therefore, excessive,
deficient, or inappropriate production and release of hormones might lead to an
imbalance of the required biological stability and in such way may contribute to the
development of certain diseases.

1.2. Neuroendocrine Responses to Psychological Stress:

Glucocorticoids and

Catecholamines
There are two main neuroendocrine pathways activated in response to psychological
stress: the hypothalamic-pituitary-adrenal axis (HP A) which when activated results in
release of glucocorticoids (GCs), and the sympathetic nervous system, which results in
the release of the catecholamines, epinephrine and norepinephrine (Marketon & Glaser,
2008). In addition, there are other neuroendocrine factors released following stress such
as growth hormone (GH) and nerve growth factor (NGF). See Figure 1.
The hypothalamic-pituitary-adrenal axis (HP A) activation follows the release of
corticotrophin releasing factor (CRF) and vasopressin which are produced in the
hypothalamic paraventricular nucleus (PVN) of the hypothalamus (Webster & Glaser,
2008). Consequently, these hormones stimulate the anterior pituitary to secrete
adrenocorticotrophic hormone (ACTH) which is released into the blood and reaches the
adrenal cortex, where it acts on the adrenal glands and causes the1jl to synthesize and
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secrete glucocorticoids (Costanzo et al. 2011; Webster & Glaser, 2008). See Figure 2.
These honnones regulate a wide variety of cellular processes via glucocorticoid receptor mediated activation or suppression of target genes. They interact with intracellular
receptors, and fonn a ligand - receptor complex that directly provides the signal to
specific genes whose rate of transcription is thereby altered (Webster & Glaser, 2008).
Glucocorticoids act by binding to GC receptors which are followed by receptor
translocation into the nucleus and trans-activation or trans - repression of target genes
(Kino, 2007). They exert their effects through their ubiquitously distributed intracellular
receptors. In the absence of ligand, the non-activated GCR resides in the cytoplasm of
cells and act as part of a large multiprotein complex consisting of the receptor
polypeptide, two molecules of hsp90, and several other proteins (Kino, 2007). Chaperon
proteins keep the GCR in an inactive state. Upon hormone binding, the receptor
dissociates from hsp90 and other proteins and translocates into the nucleus, where it
binds as a homodimer to glucocorticoid-response elements (GREs) located in the
promoter region of target genes, and regulates the expression of glucocorticoidresponsive genes positively or negatively, depending on die GRE sequence and promoter
context (Kino, 2007). See Figure 3. The receptor can also modulate gene expression
independent of GRE-binding by physically interacting with other transcription factors
such as AP-l and NF-kB; the latter protein is known to be up-regulated in inflammation
and in nearly all tumors. It is important to note that glucocorticoid's effectiveness in
target tissues is regulated by numerous factors at each step of the GCR signaling cascade
(Kino, 2007). Glucocorticoids are synthesized in a final form and secreted immediately,
'r.

so there is no intracellular reservoir of these hormones (Murray et al. 2006). Basal
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secretion of GCs is necessary for the nonnal function of many tissues. They are also
necessary for maintaining the homeostasis of the eNS, the cardiovascular system, and
metabolism. In addition, at ~ropharrnacologic" doses (10

-8

mallL) they are used as

immunosuppressive and anti-inflammatory agents for many diseases (Kino, 2007). An
excess of circulating glucocorticoids, which can occur as a result of chronic stress., is
associated with increased susceptibility to viral infections, prolonged wound healing and
decreased antibody production after vaccination (Sternberg et a1. 2006). Therefore, a fine
balance of glucocorticoids is required for the maintenance of homeostasis.
The second neuroendocrine pathway involves activation of the sympathetic nervous
system resulting in the release of the catecholamines. Catecholamines [dopamine (DA).,
levodopa (L-Dopa)., epinephrine (EP) and norepinephrine (NE)] playa significant role in
the nervous system as central and peripheral neurotransmitters (Sanghavi et a1. 2012).
They maintain notmal physical activity of the body including blood pressure, heart rate
and the reactions of the sympathetic nervous system (Kumar et a1. 2011). In addition,
very high levels of catecholamines in biological fluids may indicate neural and/or tumors
of adrenal glands (Barron, 2010). Catecholamines are synthesized in a final fonn and
stored in granules in the chromaffin cells of the adrenal medulla. In response to
appropriate neural stimulation, these granules are released from the cell through
exocytosis, and the catecholamines are released into the circulation. A reservoir supply of
catecholamines exists in the chromaffin cells, which can be released over several hours
(Murray et a1. 2006). Catecholamines initiate their biological effect by binding to
receptors located in the plasma membranes of cells and generate a signal that regulates
various intracellular functions. Catecholamines have hormone recognition and signal
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generation domains. Catecholamines bind to the

~2 -

adrenergic receptor and stimulate

activation of a G-coupled protein resulting in increased intracellular cAMP (Marketon &
Glaser, 2007).
As described above, glucocorticoids and catecholamines possess different functional
characteristics. See Figure 4. For example, cortisol is lipophilic, has transport proteins
and mediates its effect via receptor hormone complex, whereas norepinephrine is
hydrophilic, has no plasma transport proteins and mediates its effect via cAMP (Murray
et aL 2006). These different characteristics suggest that cortisol and norepinephrine may

act in a different manner with respect to the up-regulation of tumor markers.

1.3. ·Cortisol- a Biomarker of Psychological Stress
Cortisol is considered a validated biomarker for assessment of HP A axis function
(Tornhage et al. 2009). Cortisol can be measured in urine., plasma and saliva. The latter is
known to be a reliable measure of the unbound, biologically active cortisol in blood
(Weinrib et aL 2010). In plasma, the majority of circulating cortisol is tightly bound to
CBO (corticosteroid-binding globulin) and the rest to albumin. The remaining hormone is
free or unbound and is thought to be available to exert other biological functions. Levels
of cortisol found in saliva are significantly lower than those found in plasma (Matousek
et aL 2010), since salivary cortisol is more closely correlated with the free fraction in
serum than to total serum cortisol. Literature (Turner

~

Cobb et al. 2000; Sephton et al.

2009) indicates that depressed individuals exhibit higher cortisol secretion rates and have

flattening cortisol rhymes. In addition, some researchers report (Luecken & Compas,
2002) that disrupted circadian rhythms of cortisol in cancer patients"'-can lead to an earlier
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mortality as cortisol is capable of influencing neoplastic cell growth by altering cell
adhesiveness, cell division, and metastatic potential (Luecken & Compas; 2002). In
addition, some studies report that elevated levels of cortisol is positively correlated with

the severity of the disease in breast cancer patients (Banu et al. 1988; Van der Pompe et
al. 1996).

1.4. MUC1- a Biomarker of Tumor Progression
MUCl, also named DF3, episialin, CA 15-3, P AS-O, or polymorphic epithelial mucin
antigen (PEM) (Schumacher & Adam, 1998) is encoded by the MUCI gene, located on
chromosome lq21, and is expressed on the ductal cell surface of normal glandular
epithelia originating from gastro-intestinal, respiratory and urinary tracts and in breast,
ovary and testes (Papadimitriou-Taylor et aL 1998). MUC 1 is known to be overexpressed by a diverse number of human carcinomas and some hematologic malignancies

(Duraisamy et aL 2007). In malignant cells, MUCI is over expressed over the entire cell
surface resulting in increased exposure to molecules found on other tissues or blood
vessels, such as ICAM-l and shedding into the circulation;> (Duraisamy et al. 2007). This

characteristic makes Muel a valuable tumor marker. In fact, more than 20 years ago
MUCI was identified and validated as a tumor antigen. Since then it has widely been
measured in clinics using FDA approved commercially available kits (CA 15-3), as an

important prognostic marker to monitor patients' clinical treatment response, time to
disease progression and survival (Park et a1. 2007).
In summary, as mentioned above, chronic psychological stress leads to the excessive

production and release of two main stress hormones: cortisol and norepinephrine which
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mediate the response to stress

VIa

two different neuroendocrine .pathways: the

hypothalamic-pituitary-adrenal axis (HPA) and the sympathetic nervous system. Thus,
the glucocorticoid cortisol and the catecholamine norepinephrine are known to be the
markers of psychological stress. In addition, MUel is considered a validated tumor
marker which is associated with tumor cell metastasis and is aberrantly glycosylated and
up - regulated in most human epithelial carcinomas. Therefore, focusing on two main
physiological markers of psychological stress (cortisol and norepinephrine) and the tumor
marker (MUel) pennits the investigation of the effects of psychological stress on tumor
progresSIon.
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CHAPTER II
LITERATURE REVIEW

2.1. Stress and Cancer Progression
There is a long history regarding the question of whether psychological factors can
influence the etiology and progression of cancer. It has been known for a long time that
chronic, stress affects a variety of processes within the

body~

and has been linked with

adverse health outcomes. More specifically, studies have shown that psychological stress

heightens the risk of coronary artery disease (Rozanski et aL 1999), respitory infection
(Cohen et a1. 1991), and produces changes in immunity (Rabin, 1999). In terms of cancer,
the link between psychological stress and tumor initiation still remains unclear (Chen et

aL 1995; Protheore et a1. 1999). However, the link between the effect of psychological
stress and tumor progression is stronger (Chida et al. 2008; Antoni et al. 2006).

Therefore, this literature review focuses on studies investigating the effect of stress on
tumor growth and metastasis and omits studies investigating the effects of stress on the
initiation of cancer.

Thus~

this review refers to chronic psychological stress only which

persists over an extensive period of time:

days~

months., years.

Stress and cancer have been known to be linked in many ways (Chida et al. 2008;
Antoni et aL 2006). However, these connections became serious research targets just
quite recently. The complexity of psychological stress itself and methodological
limitations to measure stress are a few of the obstacles limiting our understanding of how
stress and cancer are relatedw In

general~

there are four key components in the design of

studies investigating the relationship between psychological stress and cancer: tumor
model, type of the stressor, timing of the stressor, and the
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frequ~ncy

and duration of the

stressor (Contrada & Baum., 2010). To investigate the effect of psychological stress on
tumor progression, researchers have used tissue culture, animal models and human
clinical approaches. In terms of stressors, they could be divided into two main categories
- physical and psychological. The first type refers to such stressors as heat, cold, surgery,
involving an insult to the tissues of the organism, whereas the second type induces the
anticipation of threat or harm (Strange et al. 2000). Also, there could be a psychosocial
stressor which results from the responses to the social interactions or lack of such
interactions (Strange et al. 2000). Animal model studies use the following types of
stressors: 1) restraint (an animal placed in a confined space, preventing it from moving
freely); 2) forced swimming (an animal placed in a cylinder of water); 3) and social
isolation stress (where an animal is being isolated from others) (Kemeny & Schedlowski,
2007). To measure psychological stress, researchers often focus on the following
mediators

of

psychological

stress:

the

glucocorticoid

cortisol

(CORT),

the

catecholamines norepinephrine (NE) and epinephrine (EPI), as well as the synthetic
glucocorticoid dexamethasone (DEX) (Nillson et al. 2007; Shahzard et al. 2010; Imai et
al. 2004). It is important to note that the doses of stress hortnones used in such studies are
,

selected to mimic the physiological levels of these hormones found at the site of the
tumor in cancer patients. As outlined in the introduction, it has been documented (Sloan
et al. 2010; Shimizu et al. 1994; Madden et al. 1995) that psychological stress evokes the
release of micromolar concentrations of cortisol, norepinephrine, and epinephrine into the
tumor microenvironment, but nanomolar concentrations into the systemic circulation.
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Current studies use the following markers to investigate tumor progression: VEGF
(Vascular endothelial growth factor) (Thaker et al. 2006), interleukins (Nillson et al.
2007; Shahzard et a1. 2010), MMP (Matrix metalloproteinases)(Thaker et a1. 2006; Yang
et al. 2006; Sood et at 2006; Landen et a1. 2007; Lutgendorf et a1. 2008), kinases (Thaker
et al. 2006), and various transcription factors. All of them are known to be involved in
cancer pathogenesis and therefore serve as good indicators of cancer growth and
progression. More specifically, VEGF is a protein that stimulates vasculogenesis and
angiogenesis, so high levels of this protein allows cancers to grow and metastasize
(Thaker et aL 2006). Various interleukins, such as IL-6., are known to be elevated in
cancer patients and thought to be associated with an increased tumor burden (Nillson et

aL 2007). MMPs play a big role in tumor cell invasion and migration (Landen et al.
2007). To the best of our knowledge, no studies attempted to investigate psychological
stress effect on the tumor marker MUC 1.
The data from animal models appears to demonstrate the most compelling evidence
that psychological stress might affect cancer growth and progression. A number of

studies (Nillson et al. 2007; Shahzard et a1. 2010) demonstrate that chronic stress is
"

associated with increased levels of pro-angiogenic cytokines - IL-8 and IL-6 in ovarian
cancer cell lines (SKOV3, SKOV3.ipl., Hey-A8). More specifically, treatment of ovarian

cancer cells with norepinephrine and epinephrine were shown to significantly enhance
the expression of IL-8. This effect was mediated by the ADRB2 and the FBJ murine
osteosarcoma viral oncogene homolog B also known as FOSB (in humans) or FosB (in
other species (Shahzard et al. 2010). In addition, Nillson et al. (2007) demonstrated that
""c_

norepinephrine increased the expression of IL-6. An elevated level of this cytokine is
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known to be associated with a poorer prognosis in ovarian cancer patients (Plante et a1.
1994; Tempfer et a1. 1997). Therefore, enhanced expression of IL-6 by one of the stress

hormones - norepinephrine suggests the important role psychological stress may play on
ovarian cancer progression. These studies identified f)-adrenergic receptor/Scr tyrosine
kinase signaling as the mechanism known to be critical in ovarian cancer progression.
Other studies (Thaker et a1. 2006, Yang et al. 2006; Sood et al. 2006; Landen et a1.
2007; Lutgendorf et a1. 2008) show that stress honnones can markedly increase the
expression ofVEGF, MMP9, and MMP2 in ovarian cancer cells, animal tumor models
and ovarian cancer patients. Thaker et a1. (2006) identified B-adrenergic activation of the

cAMP-PKA signaling pathway as the most important mechanism by which stress can
enhance tumor angiogenesis and promote malignant cell gro\Vth. Landen et aL (2007)
demonstrated that increasing doses of norepinephrine and epinephrine increased levels of
the phosphorylated signal transducer and activator of transcription -3 (STAT3) factor in
ovarian cancer cells. Activation of STAT3 is associated with oncogenesis (Calo et al.

2003)4
Using an orthotropic mouse model of breast cancer, Sldan et al. (2010) showed that
restrained stress led to a 30-fold increase in the size of the primary tumor and an increase
in metastasis to distant tissues including the lymph nodes and lung as measured by in vivo
optical imaging to track metastasis using luciferase -tagged 66c14. They identified
adrenergic signaling as the main mediator of this effect. More specifically,

~-

13-

adrenergic

signaling increased the infiltration of CD 11 b F 4/80 macrophages into primary tumor
parenchyma and hereby induced metastatic gene expression. These findings highlight the
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importance of the activation of the sympathetic nervous system as a novel regulator of
breast cancer metastasis.
Using an orthotopic mouse model of human ovarian cancer, Ani! et al. (2010) have
shown that restraint stress and the associated increase in norepinephrine and epinephrine
protected cells from anoikis (cells entering apoptosis when separated from ECM) and
promoted their growth by FAK (Focal Adhesion Kinase) pathway. FAK localizes to focal
adhesions and mediates physical attachment of cells to the ECM.
In addition to the numerous studies investigating the effect of chronic stress on
cancer progression in the laboratory settings, there are also studies conducted with
humans. Those studies include the assessment of such psychosocial variables as
depression, chronic stress, and social support. Chronic psychological stress which persists
over a long period of time can increase the risk of major depression. Therefore,
depression could be considered as a consequence of chronic stress. For example,
Lutgendorf et a1. (2008) showed that ovarian cancer patients with elevated levels of
depressive symptoms and low social support showed elevations in MMP9, whereas
patients with high social support and other psychosocial factors have lower levels of
,

VEGF and MMP9. It was also shown that higher levels of depression (CESD, scale > 16)
were associated with a significant increase in F AK expression and a highly significant
increase in phosphorylated FAK, a protein involved in cellular adhesion and spreading
processes.
These findings from the studies mentioned above indicate that the neuroendocrine
system plays an important role in the tumor microenvironment and the facilitating of
'".

tumor growth. Specifically., stress hormones have been shown to be capable of altering
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tumor growth by enhancing the levels of VEGF, various cytokines, MMPS,
transcriptional factors. Together, these studies offer insight into the mechanisms of how
chronic psychological stress may affect tumor progression. Indicatively, the J3-adrenergic
pathway has been hypothesized to be a main mechanism mediating the stress effect on
tumor growth and metastasis (Landen et aL 2007; Thaker et aL 2006, Yang et aL 2006;
Sood et al. 2006). The majority of these studies use ovarian cancer as a model; therefore
there is a need to explore this relationship with other cancers, especially in light of the
positive results obtained from ovarian cancer studies. Also, many studies (Nilsson et al.
2007; Landen et a1. 2007; Antoni et a1. 2006) suggest that the underlying mechanisms
mediating this effect are still poorly understood and more research is needed. Therefore,
by using cortisol and norepinephrine and looking at a different pathway, this thesis

proposes a novel mechanism by which psychological stress might alter tumor growth and
progression. In addition, since this thesis focuses on the effect of psychological stress
and highlights the importance of psychological interventions., it is essential to note that
there is disagreement within the field concerning the true impact of how psychological
interventions affect patients' survival. A landmark study led by Spiegel et al. 1989
:r

showed an 18-month survival time advantage in women with metastatic breast cancer
who had followed stress management and social support intervention. In addition,
Grossarth et a1. (1989) reported a longer survival for breast cancer patients receiving
individual psychotherapy. A significant survival advantage following participation in
group psychotherapy interventions was also reported among malignant melanoma
patients (Fawzy et a1. 1995). In contrast, several studies (Goodwin et al. 2001; Edelman
'--

et aL 1999; Gellert et aL 1993) failed to demonstrate a significant effect of psychological
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interventions on cancer progression and survival. In summary, due to mixed results on
the survival outcomes, the true impact of psychological interventions on survival of
cancer patients remains controversial, and more in depth studies addressing these issues
are needed.

2.2. MUel and Cancer

The MUCI family of molecules consists of secreted (M'UC2, MUe3, MUC5AC.,
MUC5B, MUC6) and membrane bound fonus (MUel, MUe3, MUC4, MUC12,

Mue 13, MUe 16, MUC 17) . Both types of these mucins form a physical gel barrier that
protects epithelial cells of specialized organs such as kidney; pancreas, and liver
(Duraisamy et al. 2007). Among all identified mucins, MUel has been investigated most
extensively (Li & Cozzi, 2007).
MUCI is encoded by a single transcript and after translation undergoes autocleavage
into two subunits (Kufe, 2009). The core protein of MUC 1 consists of the 20 amino-acid
tandem repeat (TR) sequence "PDTRPAPGSTAPPAHGVTSA'\ an SEA domain, and a
C tenninal cytoplasmic tail of72 amino acids (Pericleous

et al. 2005). See Figures 5-6.

if"

The TR domain contains multiple 0 - glycosylation sites, with carbohydrate being the
major portion of the mature mucin molecule (Walsh et aI., 2000; Papadimitriou et at
1999)~

The major MUCI isoform is a type I transmembrane molecule with the mucin

domain fonning a very large, rigid structure extending above the glycocalyx on the apical
surface of epithelial cells. Several alternatively spliced isoforms have been described
including a transmembrane isoform lacking the mucin domain and a secreted isofonn
>.'

~

lacking the cytoplasmic and transmembrane domains (Walsh et ai. 2000). Up-regulated
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expression of the major MUC 1 isoform is associated with gene amplification and/or

increased transcriptional activation (Walsh et aL 2000).
There are many murine antibodies produced which react with

Muel

(Taylor-

Papadimitriou et al. 1981). Most of them recognize exposed epitopes within the 20-mer
tandem repeat region. The most commonly recognized epitope is the hydrophilic
"PDTRPAP" sequence. The main antibody used in this thesis is a

humanized IgG 1k

monoclonal human milk fat globule-l antibody (huHMFG 1) that was raised against the

highly conserved and immunogenic core region of the extracellular domain of MUCI
(Taylor-Papadimitriou et aL 1981). This monoclonal antibody (MAb) recognizes and
binds with high specificity to the extracellular MUC 1 amino acid sequence, PDTR.
Studies (Verhoeyen et al. 1993) revealed that huHMFG 1 binds to only those peptides that
contain the PDTR sequence. This sequence is not exposed in normal epithelial cells, as it
is fully glycosylated and masked by the carbohydrates. In epithelial cancers

Muel

is

aberrantly glycosylated, leading to the exposure of this PDTR epitope; therefore,

HuHMFGl has a high specificity to target a wide range of MUCI over expressing tumors
and positively reacts with the human epithelial tumdr cell lines. It has been known
(Mitchell et a1. 2002) that MUel expression is recognized by huHMFGl in many cancer
cell lines which includes, but not limited to, the following: DU-145, MCF7, MB-231, and

MB-453.
Although MUel was initially identified as a tumor antigen, its gene is now known as
an oncogene involved in both tumor formation and progression (Hattrup et al. 2006).
MUCI can contribute to cancer pathogenesis via over expression caused either by the
gene itself or by other genes involved in the modification of
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tm;" MUe 1 protein. Also,

Muel is believed to be involved

In remodeling the tumor microenvironment by

promoting tumor invasion, metastasis and growth (Walsh et aL 2000; Papadimitriou et aL
1999).

The ability of the MUCl to promote tumorigenesis and tumor progression originates
from the interaction of its cytoplasmic tail (CT) with proteins involved in oncogenic
signaling (Kufe, 2009). CT' contains mUltiple serine, threonine, and tyrosine residues,
which are phosphorylated and involved in different signaling cascades. The CT can bind
and signal through (3 - catenin and the mitogen - activated protein kinase (MAPK). In

addition, CT interacts with members of the ErbB family, Wnt effector, EGFR and
participates, in their downstream signaling pathways (Kufe, 2009). By binding to these
other intracellular proteins MUel CT can migrate to the nucleus and regulate gene
expression in such a way that MUCI becomes a highly specific tumor antigen (TaylorPapadimitriou et a1. 1981; Walsh et a1. 2000; Hattrup et a1. 2006; Kufe, 2006). These
observations emphasize the importance of searching new signaling pathways that could
affect MUCI regulation.
Experimental manipulation of MUCI gene expression has indicated that MUCI

IS

capable of modifying in vitro adhesion and motifity, and is associated with increased
metastatic behavior (Walsh et a1. 2000). MUCI glycosylation is frequently perturbed in
malignant cells, with resultant truncated chains and the synthesis of sugar moieties not
normally expressed .

The extracellular domain of MUC 1 has been shown to act as a ligand for the
endothelial adhesion molecule

(ICA~11),

via sialylated carbohydrate structures known as

selectins, which have domain homology with the ligand binding domain of cytokine
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receptors (Ciborowski & Film; 2001). MUCI can interfere with integrins, receptors that
mediate attachment between a cell and the tissues surrounding it, mediated adhesion to
the extracellular matrix, and with cadherin mediated cell - cell adhesion, and can also
enhance cellular motility. ECM proteins and their receptors are thought to play an
important role in the initial stage of cancer cell attachment to the host tissue surfaces. It is
documented (Ciborowski & Finn, 2001) that unlike normal cells in which the tandem
repeat domain of MUClis 0- glycosylated at high density, tumor MUel contains
multiple chains devoid of O-glycosylation and therefore these fragments of the
polypeptide core of MUCI could be the candidates for interaction with matrix proteins
and could promote attachment of tumor cells at distant sites.
It has been known (Zaretsky et al. 2006) that Muel is predominantly hormonally
regulated. More specifically, it is known to be transcriptionally regulated by estrogen,
progesterone, and glucocorticoids. Although intensively studied, the mechanisms of
steroid regulation of MUCI transcription remain unclear. It was reported (Zaretsky et al.
2006) that estrogen increases MUCI expression. However, due to the different
arrangements of cis-elements in the MUCI promoter this could lead to the competition of
different transcription factors, the estrogen-altered expression might be cell and tissue
specific (Zaretsky et aL 2006). Progesterone has also been shown to stimulate MUe 1
expression (Wang et aL 2010). Glucocorticoid steroid response elements on the MUel
gene were identified in the 1990s (Treon et al. 1999; Mitchell et al. 2002). However, in
the following years, only a few studies have been conducted, to investigate the effects of
steroids on Muel expression.
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2.3. Glucocorticoids Expression on MUCI
In the early 1990s several groups identified consensus sequences for estrogen,
progesterone, and glucocorticoid steroid response elements on the MUCI promoter,
suggesting that these steroids may up-regulate MUC1 transcriptionally. However, in the
subsequent years only a few studies (Treon et at 1999; Mitchell et al. 2002) further
explored the effects of steroids on MUC1 expression. The full length genomic sequence
of MUC 1 (Lancaster et al. 1990) led to the identification of the glucocorticoid regulatory
elements on the Muel promoter, including core a sequence (TGTTCT, TGTTCC)
located

on

+ 38

and

321,

respectively

and

two

consensus

sequences

(GCCTGAATCTGTTCT located on +29 and AGCTGGCTTTGTTCC located at -330).
Glucocorticoid - dependent up-regulation ofMUCl has been documented in DU-14S
cells previously. Treon et aL (1999) reported that dexamethasone (a synthetic
glucocorticoid) induced MUCI expression in DU-14S as measured by flow cytometry
and western blots . More specifically, the highest induction of cell surface MUCI
expression was seen using 10 ~8 mollL (a pharmacologically achievable dose) after 24

hours treatment (Imai et a1. 2004). In DU-145 cells"" treatments with estrogen or
progesterone receptor agonist or antagonist or alone with the glucocorticoid receptor
antagonist RU486 did not alter Muel cell surface expression. Imai et al. (2004) showed
that DU-145 cells treated with 10-8 M of dexamethasone expressed maximal levels of
MUC1 after 6 days with an approximately 3-fold increase over MUC1 levels on nontreated

cells~

In addition., there was no significant difference in levels of MUel

expression, between treatments with 10-8 and 10-5 M concentrations. After 15 days of
dexamethasone treatment, DU-145 cells continued to express Muc'f at elevated levels.
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These findings~ observed by other researchers (Imai et al. 2004; Treon et al. 1999),
demonstrate that pharmacologica.lly achievable concentrations (10- 8 to 10- 5 M) of the

synthetic glucocorticoid significantly up-regulated MUC1 expression in DU-145 cells
and therefore give rise to the probability that these effects could be replicated using the
glucocorticoid cortisol.

Hypothesis
As mentioned above, although a growing body of scientific evidence demonstrates
that chronic psychological stress can affect tumor progression, the mechanisms that
mediate this effect have not been completely defined. The best identified mechanism of
how this may occur is via

~

- adrenergic signaling which was replicated by the J3 -

adrenergic agonist isoproterenol and stress responses were blocked by the J3 - blocker
propranolol in mainly ovarian cancer models. Thus, to our knowledge, no previous
studies have investigated the effect of psychological stress on biomarkers of tumor
progression, such as MUC 1. Therefore, the investigation of relationship between cortisol
and norepinephrine, as the main stress hormones, and MUC1, as a validated tumor
marker, can contribute to narrowing the gap in understanding the mechanisms mediating
psychological stress effect on tumor progression.
Based on the relationship between psychological stress and tumor progreSSIon
outlined above, this study tested the hypothesis that hormonal mediators of chronic
psychological stress alter tumor progression by up-regulating the tumor antigen Muel in
DU-145 prostate cancer cells.
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More specifically., we hypothesized that the glucocorticoid cortisol and the catecholamine
norepinephrine will up-regulate the expression ofMUCl in vitro.

Specific Aims
Specific Aim 1: To establish optimal stress honnone treatment parameters

(dose, exposure times) for cortisol and norepinephrine.
Specific Aim 2: To investigate the effect of cortisol and norepinephrine on MUC 1

expreSSIon.
Specific Aim 3: To investigate whether stress hormones can enhance the transcription of

MUCl in DU-145 cells.
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CHAPTER III
MATERIALS & METHODS

Cancer Cell Lines and Culture Conditions

Human breast adenocarcinoma cell lines MDA-MB-231 (MB-231), MCF7, MDAMB-453 (MB-453), and prostate cancer cell line DU-14S were obtained from Dr.
Fernandes of the Department of Biochemistry and Molecular Biology, Medical
University of South Carolina. Cells were maintained and propagated in vitro by serial
passage in RPMI 1640 medium (Invitrogen, # 10040CM) supplemented with 10% fetal
bovine serum (FBS) and penicillin - streptomycin (lOOU/mL) (Gibeo, # 15140-122).
Cultures were grown at 37°C in a 5% C02 humidified atmosphere and the experiments
were performed with 70 - 900/0 confluent cultures.

Reagents

Hydrocortisone (cortisol) and norepinephrine were obtained from Sigma-Aldrich (Cat

# H6909) reconstituted and stored at - 20°C. The humanized IgG 1 - type MUC 1
monoclonal antibody, huHMFGl" and its recombinant GST-MUC1 antigen were
provided by the biotech company, Antisoma Research Ltd, London, U.K.

Concentrations of Stress Hormones

The doses of stress hormones were selected to reflect physiological concentrations of
these hormones at both the circulating level (0.003 - 0.006 JlM) and the level of the
tumor microenvironment (0.1 - 1 J.lM). Prior to each experiment, stock hormones were
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diluted in RPMI 1640 medium and exposed to cells within 5 min of preparation to
minimize spontaneous degradation.

Monoclonal antibody huHMFG 1 Concentrations
HuHMFG 1 concentrations needed for measuring MUe 1 expression in each cancer
cell line were determined by Enzyme-linked Immunosorbent Assay (ELISA) doing
doubling dilutions of the antibody with the optimal concentrations generated from the
standard curves using Sigma Plot 11.0. See Figure 7.

Salivary Cortisol

Saliva was obtained from healthy volunteers and salivary cortisol was measured in
triplicate using Salimetrics kit (Cat # 1-3002) following the manufacture's protocoL
Saliva samples were collected into the Salimetrics oral swabs and were stored at - 20°C
or processed following the manufacture's protocol. Salivary cortisol concentrations were
determined using a 4-parameter sigmoid minus curve fit (Aardal & Holm, 1995).

Antigen Enzyme-linked Immunosorbent Assay (ELISA)
Microtitre plates (96-well) were coated with GST-MUCI in 0.1 M sodium carbonate
and incubated overnight at 4°C. The next day, the wells were blocked with PBS-Tween
containing BSA (1 %) and incubated for one hour at 37°e prior to the addition of
huHMFG 1 that was serially diluted using PBS. Antibody binding was detected using goat
anti-human peroxidase conjugate IgG (Santa Cruz~ # SC-2453). Each incubation step was
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followed by three PBS-Tween washes. The ELISA plate was developed with TMB
substrate (Dako, # S 1599) and absorbance at 630 run measured.

Cell Enzyme-linked Immunosorbent Assay (ELISA)
Tumor cells (1 X I05 ce lls/m l) were seeded in triplicate into wells ofa 96-well cell
culture plate and incubated overnight at 37°C. The next day, the cells were fixed by
replacing the medium with 4% fonnaldehyde in IX PBS and incubated for 15 min at
room temperature. Triplicate wells in each treatment group were left without fixation for
cell counting . Formaldehyde was removed by aspiration with a pipette. The plate was
washed by pipetting [(3X 300 fll) of PBS + Tween 20 (0.05%)] into each well., and the
liquid was discarded by inverting the plate. After each wash, the plate was thoroughly
blotted on paper towels before being turned upright. Following the addition of 100 fll of
incubation buffer (PBS +Tween 20 (0.05%) + 3 % (w/v) BSA) into each well the plate
was incubated for 1hr at 37°C. Appropriate concentration ofhuHMFGl was added and
the plate incubated for 1.5 hour at 37°C. For detection, 100 f.ll of peroxidase conjugated
goat anti-human IgG was diluted 1:2000 in wash buffer/'and the plate was incubated for
one hour at 37°C. The ELISA colorimetric assay

was developed using 100 ~l of the

TMB substrate added into each well and the plate was read at 630 every 5 min until
maximum absorbance was measured.
In order to control for any variations in cell number among the

wel1s~

additional wells

were not subjected to fixation but were trypsinized by adding 40 JlI of Trypsin/EDTA
(0.05%) into each well and incubated at 37°C for 5 min. Then the plate was placed on the
shaker for 8 min followed by addition of 80 Jll of RPM! 1640 tissue culture medium.
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Cells were counted using a hemacytometer. Final absorbance was calculated by taking
the optical density value with subtracted background and dividing it by the cell number
count in each treatment group.

The Bradford Colorimetric Assay (DCA)
Protein standards were prepared using bovine serum albumin (BSA) (Thermo
Scientific, # 23210) according to the manufacture's protocol. The reagent blank
containing only PBS and Coomassie Plus Reagent

(Pierce~

# 23236). A standard curve

was generated by plotting the average blank-corrected 595 run measurement for each
standard versus its concentration in J.1g/ml ofBSA. To measure total cellular MUCI
protein, non - fixed cells from the cell ELISA assays were sonicated in PBS three times
for 10 seconds each in a VirSonic sonicator (VirTis., Gardiner). After adding Coomassie
Plus Reagent to all of the sonicated experimental samples, the absorbance values of the
samples and reagent blanks were measured at 595 run following 10 min incubation at
room temperature. Each sample was assayed in triplicate. The average absorbance at
595 run for the reagent blank was subtracted from the absotbance at 595 om of the
experimental samples. The protein concentration of the samples was then determined by
comparison of the net absorbance of the samples to the absorbance values of the BSA
standard curve.

Flow Cytometric Analysis
Cell surface expression ofMUCl on DU-145 cells was examined and quantified by
flow cytometry. Cells were harvested from 75 cm2 flasks by washing wIth sterile PBS and
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dissociation with Trypsin/EDTA (0.05%). Cells were washed twice with ice-cold PBS
and 106 cells were resuspended in IX PBS containing 10 - 20llg/ml of huHMFG 1 for 2
hours at 4°C in a volume of 1 ml. Goat anti-human IgG -PE (Santa Cruz, # SC-3736)
secondary antibody was then added and incubated for 1 hour at 4°C in the dark. Each
antibody incubation step was followed by centrifugation (5 min, speed 4) and
resuspension of cells in 1 ml cold PBS. Flow cytometry data were analyzed with
CellQuest™ from Becton Dickinson.

RNA Isolation and Reverse Transcription peR
Total cellular RNA was isolated from treated and untreated cells using Trizol reagent
(Invitrogen, # 15596-026) following the

manufacturer~s

instructions. The RNA was

quantified by spectrophotometry at 260 and 280 nm. Equal amounts of total RNA (5J..lg)
from each sample were reverse transcribed using a High-Capacity eDNA Reverse
Transcription Kit (Applied Biosystems, # 4368814). The resulting cDNA was amplified

by PCR using primer pairs for the MUel (forward 5 'GGTACCTCCTCTCACCTCCTCCAA-3~;

reverse 5' -,"

CGTCGTGGACATTGATGGTACC-3') and the GAPDH (forward 5'TGCACCACCAACTGCTTAGC-3"; reverse' -GGCATGGACTGTGGTCATGAG-3 ').
MUCI primers were obtained from Fisher Scientific. GAPDH primers were provided by
Dr. Spicer, Department of Biochemistry and Molecular Biology, MUSe. PCR was
carried out for 35 cycles at 94°C for 30s, at 60°C for 1 min and 72 DC for 1 min.
Products were then separated on a 1.5% agarose gel, stained with ethidium bromide and
'-I
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visualized under ultraviolet illumination. Product formation was quantified by
determining the integrated density value of each band.

Real Time -peR
Real-time CRT-peR) was perfonned in triplicate and included GAPDH as a reference
gene. For the 25-lll reactions, eDNA (2 tJ,1) was mixed with 12.5 1-11 of Maxima SYBR
Green/Fluorescein q peR Master Mix (2X) (Fermentas, # K0241), 3 J.ll of forward

primer, 3 J..11 of reverse primer, and 4.5 f.11 of nuclease-free water. Amplification was
perfonned on Bio-Rad Thennal cycler at 50°C for 2 min and 95 °C for 10 min, followed
by 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. Data were analyzed

with automatic baseline and threshold settings for cycle threshold (Ct) determination. The
levels of expression ofMUCl mRNA in each sample were normalized to the GAPDH
mRNA levels. The final relative expression ofmRNA species was calculated using 2-delta
Ct

method.

Matrigel Migration Assay
The membrane invasion culture system chamber was used to measure the in vitro
invasiveness of the DU-145 cells. Cells were incubated with 0.1 JlM of cortisol and
norepinephrine for 1,3, or 10 days. Matrigel (Becton-Dixon, # 356230) was thawed
overnight at 4°C. Plates and pipettes were chilled at -20°C. The matrigel was then diluted
to 2 mg/ml in serum free-cold RPMI 1640 culture medium and 100 J.!l of the diluted
matrigel was placed into the upper chamber of a 24-well transwell plate (Becton-Dixon, #
35478). The plate was incubated at 37°C for 4 -5 hours to allow gelling. Cells were
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harvested from tissue flasks by TrypsinlED'TA, washed three times with RPMI 1640
containing 1 % FBS and then resuspended in RPMI 1460 containing 1% FBS at a density
of 106 cells/mL The lower chamber of the transwell was filled with 600 1-11 of culture
medium containing 5 fJ.g/ml fibronectin as an adhesive substrate. The matrigel was gently
washed with serum free culture medium. 100 III of cell suspension was placed onto the

matrigel and the plate was incubated at 37°C for 20-24 hours. After the incubation,
transwells were removed" fixed with 4% parafonnaldehyde and stained with a crystal
violet. Noninvasive cells were scraped off the upper chamber of the transwell with a
cotton swab and the cells were counted under a light microscope. To validate cells
quantification, pictures of invaded cells were taken using Q Capture Pro software. All
assays were done in triplicate and repeated once.

In Vitro Scratch Assay

Prior to conducting this assay, DU-14S cells were grown in T 25 flasks and were pretreated for 3 and 6 days with 0.1 JlM of cortisol, norepinephrine, and both stress
honnones, then cells were plated into 6 -well plates to create a confluent monolayer and
incubated for approximately 24-48 hours at 37°C allowing cells to adhere and spread.
Upon reaching confluency, the cell monolayer in each well was scraped with a p200 pipet
tip in a straight line to create a "scratch". Scratches were made of approximately similar
size in the assessed cells and control cells to minimize any possible variation caused by
the difference in the width of the scratches. The debris was removed by washing the cells
once with 1 ml of PBS and then fresh RMPI 1640 medium was added into each well.
"'--

Cells were placed in the incubator at 37°C for approximately 24 hrS. After the incubation,
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cells were washed with PBS, fixed with 4% paraformaldehyde for 20 min and stained for
15 min with crystal violet. Photographs were taken using Q Capture Pro software and by
choosing the same reference point for each treatment condition. Five images were
obtained for each well focusing on all directions of the scratch.

Cell Growth
DU -145 cells were seeded at 2 x 104 cells/ml in separate tissue culture dishes (Falcon,

# 353004) containing standard culture medium (RPMI 1640) supplemented with 10%
fetal bovine serum. This time point was considered day O. Following 24-48-72-96h
incubation at 37°C with 50/0 CO 2 • Growth studies were performed in triplicate, where
three separate measurements were obtained per day. Growth was determined by cell
counts after day 0, at 24-48-96 hour

intervals~

by using a Beckman Coulter counter.

Results denote the average of triplicate measurements repeated three separate times.
Statistical analysis compares the absolute numbers between groups at corresponding time
points. Population doublings were calculated during the logarithmic growth phase by
using Prism 4.03 GraphPad software.

Statistical Analysis
Statistical analyses were perfonned using SPSS.16 software. Statistical differences
between the groups (untreated and treated cells) were assessed either using student t-test
(taking 2-tail probability <0.05/0.01 as significant) or analysis of variances (ANOVA).
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CHAPTER IV
RESULTS

Specific Aim 1: To establish stress hormone treatment parameters: concentration
and exposure times.
A. Validating huHMFGl Binding in Different Cancer Cell Lines.
To verify that each cel1line expressed MUel, the binding capacity of HuHMFGl to
each cell line (DU-145, MCF7, MDA-MB-231, and MDA-MB-453) was determined by
ELISA. Binding curves were fitted to a sigmoidal 4-logistic equation (Sigma Plot) and
huHMFGI concentration was determined by looking at the saturation levels. These assays
revealed that the highest binding capacity was observed in the DU-14S cell line which
was selected as the main cell line to be used in our work for this thesis. See Figure 7.

B. Determination of Stress Hormone Concentrations.
Since there are no studies conducted to our knowledge on uSing stress hormones
concentrations with respect to the tumor antigen MUel, the first sets of experiments
were aimed at determining the concentrations of cortisol and norepinephrine to be used in
following experiments. Our initial intention was to use just one stress honnone - cortisol.
However, some studies (Antoni et aL 2006) have s'uggested that during acute stress, not
only cortisol, but also norepinephrine is released., and that these two hormones may act in

a synergistic or additive manner which in turn could lead to even greater impact on
cancer related processes. Therefore, later in this project, we added norepinephrine as an
additional stress honnone in our experiments. Thus, the rationale to add another stress

honnone was based on the observed effects of norepinephrine on ovanan cancer
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progression, such as enhanced expression of VEGF, MMP2, and MMP9 (Thaker et al.
2006).
It is well established that salivary cortisol is found to be a reliable surrogate for
measuring circulating cortisol, so initially we aimed to mimic the physiological
concentrations of salivary cortisol found in healthy stressed individuals. Previous studies
(Turner - Cobb et al. 2000; Sephton et al. 2000) showed that the circulating level of this
hormone in saliva is around 3-6 nM in healthy humans and is higher in distressed
individuals. Additional experiments conducted with human saliva samples confirmed that
healthy subjects' salivary cortisol level is around 0.003 J.!M. Based on this reasoning., we
increased the nonnal salivary cortisol level found in humans by several fold, and used the
following concentrations for in vitro experiments (J..lM): 0.0033, 0.0066, 0.0132, 0.025,
0.05, 0.075. Experiments conducted using these cortisol concentrations did not show any
significant enhancement of MUC1 expression. See Figures 9-11. However, it was
reported that psychological stress evokes the release of micromolar concentrations of
cortisol and norepinephrine into the local tumor microenvironment, but nanomolar
concentrations into the systemic circulation (Sloan et at. 2010; Shimizu et al. 1994;
Madden et al. 1995). This phenomenon could be explained by the hypervascularisation
of the tumor environment, which compared to normal tissue requires significantly higher
concentration of hormones and gro\Vth factors than those found in the peripheral
circulation (Flint et. al. 2009). Since this study was designed to look at disease
progression and not the onset of the disease, we estimated the experimental stress
hormone concentrations to be around 0.1

~M
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- 1 J.lM, which mimic the physiological

levels of circulating cortisol and norepinephrine generated during acute stress in the
tumor microenvironment (Flint et al. 2009).

c. Determination of Stress Hormones Exposure Times.
A lack of evidence on investigating the effect of cortisol and norepinephrine on the
expression of Mue 1 led us to experiment with a broad range of exposure times ranging
from 1 day to 58 days. Based on very few studies (Imai et a1. 2004) showing MUCI
enhancement in DU-145 prostate cancer cells after treating them with dexamethasone
(synthetic glucocorticoid) for 3 to 15 days treatment, all our experiments were conducted
with cells treated with stress hormones for 3, 6 and 10 days.

D. Preliminary Experiments Investigating MUCI Expression in Various Cancer
Cell Lines: MCF7, MDA-MB-231, and MDA-MB-453 Cells Using Cell Based ELISA
Assay.
Initially, prior to choosing the DU-145 cancer cell line as the main experimental
model to test our hypothesis, other cancer cell lines (MOP?, MDA-MB-231, and MDAMB-4S3) were also tested for MUC1 expression. The choice to use breast and prostate
cancer cell lines were based on the fact that these two types of cancer are honnonally
driven. Early experiments were designed to obtain preliminary data on determining which
stress honnone concentrations to use.
Varying concentrations of cortisol (0.003 - 0.0132 J.lM), there was a decrease seen of
MUC 1 expression in MCF? cells. Norepinehrine (0.1 JlM) alone slightly, but not

significantly, increased the expression ofMUC1 on MCF? cells. See'" Figure 9.
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Using concentrations of cortisol (0.025 - 0.5 JlM) on MDA-MB-231 cells, there was a
lack of a consistent pattern of MUC1 expression. Apart from treating cells with 0.1 J,lM,
all other concentrations either had no effect or had a down - regulation effect on MUCI
expression. See Figure 10. MDA-MB-453 cells treated for 2 and 10 days with
norepinehrine (0.1 flM) alone had a slight increase in MUCI expression. See Figure 11.
Later preliminary experiments included DU-145 cells treated with stress honnones for
3 and 58 days. See Figure 12. After seeing a significant increase in MUCI expression,
these experiments gave rise to the use of the DU-14S prostate cancer cel1line as the main
in vitro model for testing our hypothesis.
In summary, preliminary experiments conducted with different cancer cell lines and
different stress hormone concentrations and exposure times helped to detennine which
cancer cell line to use and for how long to treat cells with cortisol and norepinephrine .
As a result of these experiments, we decided to choose DU-145 prostate cancer cell line
and to treat these cells with 0.1 f.lM of cortisol and norepinephrine.

Specific Aim 2: To investigate the effect of stress hormones on MUCI expression.

A. Alteration of Cell Growth in DU-145 Cells by CORT and NE.

Cell growth experiments revealed that DU-145 cells treated with cortisol and
norepinephrine grow faster than un-treated cells. See Figure 8. This suggests that treated
cells may have a higher proliferative capacity as compared to untreated cells.
Significantly increased growth of treated cells was observed after 4 days (* P< 0.001)
compared with untreated cells using t-test analysis.
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B. Investigating MUCI Expression in DU-14S Cells Using Cell Based ELISA Assay.
To examine the effect of stress honnones on MUCI expression in DU-145 cells, the
cells were stimulated with physiologically relevant concentrations (0.1 JlM) of cortisol
and norepinephrine for 3,6, and 10 days and assayed for MUCI expression by cell based
ELISA. In an attempt to be certain that the measured absorbance (00 630) was not
influenced by possible differences in cell number between the experimental groups, cells
were counted in each treatment group prior to fixing them. Results are presented in two
formats: absorbance values not adjusted for the cell number and absorbance values
adjusted for the cell number. Since one day prior to the experiment cells were harvested,
transferred into 96-well plates, and left overnight to attach, the cells did not have much
time to grow. Therefore, we did not expect to see a significant difference in the number
of cells between treated and un-treated cells. Data generated from at least two
independent experiments for each time point revealed the same pattern of an increased
MUCI expression in cells treated with cortisol alone. See Figures 13-15.This increase
became statistically significant after 10 days of treatment. In terms of the extent of
increased expression, an approximately 1.S-fold increase:in expression was seen after all
exposure times in cells treated with cortisol. Norepinephrine alone did not have any effect
on MUCI expression at any time point. In conclusion, 6-10 days stimulation of DU-14S
cells with cortisol alone noticeably enhanced MUClexpression. Although data suggest
that cells treated with both stress hormones for 10 days had a significant increase in
MUCI expression, however since norepinephrine alone did not have any effect, this
increase was likely caused by cortisol alone.
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c. Cell Surface Expression of MUCl Assayed by Flow Cytometry.

After observing the effect of stress hormones on MUCI expression, as measured by
ELISA, we further sought to investigate this increased expression by using flow
cytometry, hence testing for similar effects by two orthogonal methods. Results are
presented as mean fluorescence intensity of the hormone treated cells normalized to the
mean fluorescence intensity of the untreated control cells. Flow cytometric analyses taken
from two independent experiments performed with untreated and treated (3, 6, 10 days)
DU-145 cells revealed a significant (p> 0.05) up-regulation of MUCI by cortisol alone
during all exposure times. See Figures 16-19. More specifically, 3 and 6 day exposure to
cortisol alone resulted in a 2-fold up-regulation ofMUCl. In addition, a 10 day exposure
to stress hormones resulted in continuous up-regulation with a 7-fold increase when cells
were treated with cortisol alone. Norepinephrine alone did not have any effect on MUC1
expression levels., irrespective of the incubation time. Therefore when cells were treated
with both stress hormones and resulted in a significant increase in MUCI expression, this
effect was caused by the cortisol alone as was observed by the ELISA assay.
In summary, flow cytometry experiments show that cortisol alone can significantly
up-regulate MUel cell surface expression in DV-14S cells. Since it is well accepted
(Snijdewint et a1. 2001) that in malignancy MUCI loses its polarized expression and is
expressed on the whole cell surface, this finding indicates that cortisol may increase the
cell surface expression of MUC 1 which could lead to tumor progression and metastasis.
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D. Measuring MUCI Levels Expressed as a Function of Total Cellular Protein by
the Bradford Colorimetric Assay (BCA).
To further examine whether the exposure to stress hormones leads to an increase in
MUCl protein levels, DU-145 cells were treated with cortisol and norepinephrine for 3,
6, or 10 days and total protein amounts were assayed by the BCA assay. This assay alone
measures just the total protein amounts, and it does not measure specifically the levels of
MUCl protein. Therefore, in order to nonnalize MUel protein levels to the total cellular
protein level, the total absorbance obtained from the ELISA assay was divided by the
total protein amount obtained from the BeA assay. In this way the Muel levels were
normalized to the protein level. See Figures 20-22.
Data generated from three different exposure times revealed that treatment with stress
hormones led to the increase in MUel protein levels at each time point. After adjusting
for the cell number, the amount of MUClprotein in cells treated with cortisol alone was
approximately 2-fold higher as compared to untreated cells at each time point. See
Figures 20-22. In summary, treatment with cortisol alone appears to increase the
MUClprotein levels in DU-l4S cells at each time point.''<

E. Assessing Migration and Invasion of DU-145 cells.
The effect of stress hormones on DU-145 cells invasion and migration was assessed

by the matrigel migration assay. The matrigel matrix serves as a reconstituted membrane
in vitro and blocks non - invasive cells from migrating through the membrane. Therefore,

cells migrating through the membrane are considered to have increased invasive
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properties. Cells were pre-treated with 0.1 J-lM of cortisol., norepinephrine., or both stress
honnones for 3., 6., or 10 days and then tested for migration efficiency twice.
Results are presented as the average number of invasive cells/field. Data show that
norepinehrine alone did not influence migration of DU-145 cells at any time point.
Treatment with cortisol consistently increased the migration by approximately 1.4- fold.
Interestingly., the combination of both stress honnones led to the highest migration
(increased by 3 -fold) after treating the cells for 6 days. See Figures 23-25.
In summary, the matrigel migration assay results show that treating DU-145 cells with
cortisol may increase the invasive potential of prostate cancer cells, possibly allowing
them to invade into the extracellular matrix which is a critical requirement for tumor cell
metastasis. Unexpectedly, data indicate that cortisol and norepinephrine acted in a
synergistic manner by increasing DU-145 cells migration after the cells were treated with
both stress hormones for 6 days (see Discussion).

Specific Aim 3: To investigate whether stress hormones can enhance the
transcription of MUCI in DU-145 cells.

A. Measuring MUCl mRNA levels.

To further define the mechanisms by which stress hormones regulate MUCI
expression in DU-145 cells, we examined whether the up-regulation of expression of
MUC 1 was a result of stress honnone- dependent transcriptional regulation. DU -145 cells
were cultured in the presence of 0.1 J-lM cortisol., norepinephrine and both stress
honnones for 3, 6, or 10 days, and MUCI mRNA levels were measured by RT - peR.
'",'

This concentration of hormones was used because it resulted in the most robust effect in
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previous experiments. All experiments were done twice. Results are expressed In
normalized fold expression compared to the house keeping gene - GAPDH.
Three days treatment of DU-145 cells with cortisol or norepinephrine alone or in
combination did not show any alteration of MUCI mRNA levels. More specifically., the
normalized fold expression for the above mentioned treatment groups were as follows:
cortisol alone (1.2 - fold), norepinephrine alone (0.5 - fold), and both (O.9-fold). See
Figure 26. However, 6 day stress honnone treatment produced up-regulation of MUCI
mRNA levels, with a 6 - fold increase in cells treated with cortisol., a 2 -fold increase in
cells treated with norepinephrine and a 3.6-fold increase in cells treated with both stress
hormones. See Figure 27. Continuous exposure (10 days) to stress hormones upregulated Muel mRNA levels in DU-145 cells treated with cortisol (with a maximum of
3.5 - fold increase). See Figure 28. Norepinephrine alone did not have any effect on
mRNA levels ofMUCl.
These results indicate that 0.1 11M of cortisol alone alters

Mue 1 mRNA levels after 6

and 10 days treatment. Interestingly, the combination of cortisol with norepinephrine had
a smaller effect on mRNA levels than cortisol alone. Further experiments should be
designed in order to investigate the possible mechanisms accounting for the increased
levels ofMUCl mRNA.
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CHAPTER V
CONCLUSIONS
There are two maIn systems activated within the human body during chronic
psychological stress: the sympathetic nervous system and the pituitary adrenal axis. They
mediate the response to stress by the release of glucocorticoids and catecholamines. The
data outlined in the literature review indicate that these hormonal mediators of stress can
contribute to cancer growth and progression. However, as of today, there is a lack of
evidence delineating the biological mechanisms involved. Using an in vitro system, this
thesis represents a novel study of biochemical links between psychological stress
hormones and Mue1 antigen expression. Building upon previous research, we
hypothesized that the glucorticoid cortisol and the cathecolamine norepinephrine will upregulate the expression of the tumor marker MUe 1.
Data arising from the three specific aims show that treating DU-145 prostate cancer
cells with physiologically relevant concentrations (0.1 JlM) of cortisol results in 1)
alteration of DU-14S cell growth; 2) enhancement of MUC1 expression; 3) alteration of
..

DU-145 cells invasive potential; and 4) an increase in MUC1 mRNA levels. In contrast,
the catecholamine norepinephrine does not have any notable effect on Mue1 expression.
See Figure 30. Based on initial experiments conducted with different cancer cell lines
and different stress hormones concentrations, MUel expression was found to be cancer
cell line specific and to depend on the stress honnones concentration used as well as on
the exposure times. For example, cortisol (0.1 J..lM) had a down-regulation effect of
MUCl expression on MCF7 cells, but up-regulation effect on DU-145 cells. Also, the
"",,,.

longer the cells were exposed to cortisol, the higher decrease of-MUC1 expression was
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observed in MCF7 cells. See Figures 9-12. Based on ELISA assay, 10 days stimulation
of DU-l45 cells with cortisol alone significantly enhanced Muel expression.
Furthermore, flow cytometric analyses revealed a significant up-regulation of MUel by
cortisol during all exposure times. In addition, data arising from the combined analysis of
Muel expression obtained from ELISA and the BeA assay revealed that pre-treatment
of DU-145 cells with cortisol for 3, 6, or 10 days resulted in approximately 2-fold
increase in MUCI protein levels as compared to un-treated cells at each time point. The
data from the matrigel assay suggest that treating DU-14S cells with cortisol for 3 - 10
days may increase the invasive potential of prostate cancer cells. Finally, RT - peR
results indicate that the concentration of 0.1

~M

of cortisol alters Muel mRNA levels

after 6 and 10 days treatment, and therefore the up-regulation of MUC 1 might be the
result of increased transcription or increased mRNA stability.
It is important to note that although it may seem that there is a consistent pattern
indicating that cells treated with cortisol in combination with norepinephrine have a
higher MUCI expression as compared to un-treated cells throughout all the experiments.
However, data show that norepinephrine alone does '<-not have any effect on MUCI
expression and therefore although it seems that cells treated with both stress honnones
have higher expression of MUC 1 as compared to un-treated cells, this effect is caused by
the cortisol alone.

This study using in vitro model investigates psychological stress effect on tumor
progression with a greater experimental control and validity as compared to other
experimental models regarding the identification of mediating processes involved. More
'"' ~

specifically, we propose the following pathway as a potential mechanism by which stress
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hormone cortisol can up-regulate MUCl expression: first., chronic psychological stress
leads to the release of cortisol which binds to the glucocorticoid receptor and then
associates with hsp90. Second., it dissociates from hsp90 and translocates into nucleus
where it binds as a homodimer to GREs located in the promoter region of MUCI and
from there it regulates the expression of MUe 1.
In conclusion., this study combined with other reports discussed in this thesis, explores
two neuroendocrine pathways as potential mechanisms mediating the effect of chronic
psychological stress on tumor progression. More specifically, the hypothalamic-pituitaryadrenal axis (HPA) which results in release of glucocorticoids (GCs) was found to
influence MUCI expression in DU-145 prostate cancer cells. In contrast, another
neuroendocrine pathway, involving the sympathetic nervous system, which results in the
release of the catecholamines, epinephrine and norepinephrine, was not found to
influence MUe1 expression in DU-145 prostate cancer cells. Since we hypothesized that
both the glucocorticoid cortisol and the catecholamine norepinephrine will up-regulate
the expression of MUel in vitro, our results indicate that the glucocorticoid alone upregulated the expression of MUel, whereas the norepinephrine alone did not influence
the expression ofMUCl.
Our finding that physiologically relevant concentration of cortisol, found at the level
of the tumor of stressed individuals, enhances the tumor antigen MUCI expression in
DU-145 prostate cancer cells adds to the knowledge of existing mechanisms by which
psychological stress may affect tumor progression. Thus, since it is well known that the
abundant expression of MUC 1 correlates with metastasis (Papadimitriou et aL 1999) data
presented in this thesis may provide a suggestive link betWeen high levels of
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psychological stress and poorer prognosis in prostate cancer patients.

However~

in order

to conclude that chronic psychological stress may influence tumor progression in cancer
patient populations, further studies must be designed as the definitive answer to this

question must await further advances in this field.
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CHAPTER VI
DISCUSSION
As already discussed, there is growing experimental and clinical evidence suggesting
that chronic psychological stress is associated with cancer growth and progression
(Thaker et aL 2006, Yang et al. 2006; Sood et al. 2006; Landen et al. 2007; Lutgendorf et
al. 2008). The purpose of this study was to investigate the biochemical and molecular
effects of the stress honnones cortisol and norepinephrine on the expression of the tumor
antigen MUCI. We hypothesized that the glucocorticoid cortisol and the catecholamine
norepinephrine will up-regulate the expression of MUCI in DU-145 prostate cancer cell
line.
Prior to establishing robust experimental conditions, initial experiments were designed
at selecting the most suitable hormone responsive cancer cell line, stress hormones
concentrations, and exposure times. See Figures 9-12. Data arising from initial
experiments show the difference in MUC 1 expression across different breast cancer cell
lines. The estrogen-dependent nature of some breast cancer cell lines as well as the lack
of cross-talk with the MUCI receptor could explain whywe did not see an up-regulation
of cortisol on MUCI expression (Lippman et al. 1976). For example, 3 and 15 days
treatment with cortisol decreased MUCI expression in MCF7 cells. Since it is known
(Lippman et al. 1976) that the interaction of estrogen with specific cytoplasmic receptor
molecules is the first step in the pathway through which steroid hormones regulate
phenotypic expression in breast cancer cells, the lack of estrogen in the tissue culture
media can explain the down-regulation of MUCI expression in MCF7 cells. In addition,
Lippman et al. (1976) reported that treatment with dexamethasone"'~l 0-7 M has inhibitory
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effect on MCF7 cells and that cortisol inhibits DNA synthesis in MCF7 cells. In contrast,
norepinephrine alone had a small effect of MUe 1 expression in MCF7 and

MDA~MB-

453 cells after treating them for 2, 3, or 10 days. See Figures 9B and 11. Since
norepinephrine binds to the

J3-

adrenergic receptor and both of these cell lines expresses

this receptor, a small effect on Muel expression in MCF7 and MDA-MB-453 cells was

seen. After collecting preliminary data on treating different cancer cell lines with different
concentrations of the stress hOffilones and varying exposure times, we decided to choose
DU-14S the prostate cancer cell line as an experimental model to test our hypothesis and
treat cells with 10-7 M of both stress hormones for 3, 6, or 10 days. In addition, the
decision to expose cancer cells to stress honnones during these specific time points was
based on previously published study showing MUCI up-regulation by synthetic
glucocorticoid in DU-14S prostate cancer cells using similar exposure times (Imai et aL
2004).

The key finding of this study is the identification of the glucocorticoid pathway which
mediated the up-regulation of Mue 1 in DU-145 prostate cancer cells. More specifically,
~'.

data derived from experiments indicate that physiologically relevant concentrations of the
glucocorticoid cortisol found at the site of the tumor in patients under chronic
psychological stress (10-7 M) (Sloan et al. 2010; Shimizu et aL 1994; Madden et al. 1995)
up-regulates tumor antigen MUe1 under protein and mRNA levels in DU-145 prostate
cancer cell line. The protein levels of MUCI antigen were assayed by cell based ELISA
and flow cytometry. The latter technique yielded a higher expression of MUCI than
ELISA. This could be explained by the fact than in flow cytometry the detection of

Muel

is determined while the protein is in suspension, whereas in ELISA the protein is
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bound to the plate. Therefore, if washing away nonspecifically bound materials fails, the
detection of specific protein may become inaccurate. In addition, to nonnalize MUCI
protein levels to the total cellular protein level, the Bradford Colorimetric Assay was used
in combination with the ELISA assay. Data extracted from these assays show that cells
treated with cortisol alone for 3-10 days up-regulated Muel

expression by

approximately 2-fold at each time point with the highest up-regulation (7-fold) observed
in cells treated for 10 days as assayed by flow cytometry. See Figure 30. These findings
are consistent with the literature (Imai et a1. 2004) which documents MUCI up-regulation
with synthetic glucocorticoid dexamethasone (10- 8 M). Norepinephrine alone did not
influence MUCI expression at any time point in any of the experiments. The migration
assay revealed that treating DU.. 145 cells with cortisol may increase the invasive
potential of prostate cancer cells.. Stress honnone mediated invasion was observed by
other researchers as well (Sood et aL 2006). Specifically, this study demonstrated that
norepinephrine, epinephrine, and cortisol enhanced the invasive potential of certain
ovarian cancer cells.
In addition to the observed increased in protein le<'els of MUCl, we also saw an
increase in MUCI mRNA levels after treating cells with cortisoL More specifically.,
treating DU-145 cells for 6 or 10 days, we observed a 6 and 4 -fold increase in mRNA
levels. Since we saw an increase in protein levels of MUC 1 during these exposure times,
we also expected to see an increase of the mRNA levels. However., our data revealed that
3 day treatment did not increase the levels of mRNA in DU-145 cells, but resulted in the
increase of the amount of a protein being produced as measured by ELISA and flow
"-.

cytometry. No changes of mRNA concurrent with up-regulation of protein expression
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may occur when a protein half-life is increased due to stabilization or by the increased

translation.
Unexpectedly, although consistent throughout all the experiments, norepinephrine
alone did not have any effect on MUCI expression in DU-145 prostate cancer cells. As
was discussed in the literature review., it has been suggested that norepinephrine can
promote various steps essential for tumor metastasis; including invasion and migration,
through activation of the tumor cell cyclic AMP protein kinase signaling pathway by the
~-adrenergic

receptor (Thaker et al. 2006, Yang et al. 2006; Sood et at 2006; Landen et

al. 2007; Lutgendorf et al. 2008). Since the current study has focused on the
glucocorticoid receptor, it is plausible to assume that the lack of norepinephrine effect
was due to the experimental design of the study which did not include any assessments of

the p-adrenergic receptor. Furthennore, it has been documented (Shi et al. 2007) that
most of the adrenergic receptor in DU-145 cells is localized in intracellular compartments
in a nonfunctional state. Assuming that norepinephrine acts via andrenergic receptor
pathway, these findings may explain why norepinephrine alone did not alter the
expression ofMUCl in DU-145 prostate cancer cells.

'/

Findings of this study should be viewed in "light of certain considerations and
limitations.

First, from the data presented above, it is unclear whether the detected

enhancement of MUC 1 expression is due to the glucocorticoid receptor. In order to
address this possibility, future research should include the use of the glucocorticoid
receptor antagonist - RU 38486 and detennine whether the stress hormones effect on
MUCI could be blocked by the use ofRU 38486.
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Second, cortisol, as it was mentioned in the introduction, does· not function in
isolation. It is just one of several chemical mediators of the stress response.
Catecholamines, cytokines, and other glucocorticoids are just a few of the physiological
mediators that may work in a synergistic manner along with cortisol and future studies
using a more complex combination of these mediators may contribute to a more

comprehensive understanding of the psychological stress effects on tumor progression.
Third, although the data suggest that DU-I45 cells treated with cortisol for 6 and 10
days increased the mRNA levels, the nature of this increase is unknown. Future
experiments should investigate whether this increase is due to increased transcription or
increased mRNA stability.
Finally, an in vitro model system just artificially mimics the stress response. It is
extremely limited and cannot reproduce what happens at the cellular and molecular level
in the body where there are complex arrays of mediators which may have a hugely
different effect on stress hormone induced MUCl expression, to that seen in in vitro
systems. However, as of today, this work offers the only direct biochemicallink between
the mediators of psychological stress and Muel expression in prostate cancer cells.
Further research could be done in a number of ways, including the investigation of
additional mechanisms of MUCI up-regulation by stress honnones, and by targeting
MUC 1 for immunotherapy with two potential therapeutic approaches: monoclonal
antibody therapy and cytotoxic T cell killing therapy. The first approach would include
targeting over-expressed MUe 1 with HMFG 1 IgG hence inducing NK cell and Cytotoxic
T cell killing by antibody-dependent cell-mediated cytotoxicity. The second approach
"'.,

would include activation of autologous T cells using peptide'S from the MUCI core
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protein resulting in antigen processing and co-expression with MHC Class II and re infusion of cells back into the patient. Also, additional research should include studies
designed to look at the psychological stress effect on the initiation of the cancer, not only
at the progression of the tumor.
Although our understanding of the bio-behavioral influences on cancer pathogenesis is
expanding, however, the molecular pathways mediating this effect have not been
completely delineated. Since, to the best of our knowledge, there are no studies
conducted investigating the effect of the stress honnone cortisol on the expression of
MUC 1, therefore, the results of this study greatly contribute to our understanding of how
physiologically relevant concentration (10. 7 M) of the stress honnone cortisol found at the
site of the tumor could lead to the increase in the tumor antigen MUel in prostate cancer
cells.
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CHAPTER VII
SIGNIFICANCE
Cancer diagnosis and treatment can lead to dysregulation of psychological and
biological processes. The activation of the pituitary adrenal axis leading to increased
levels of cortisol have been associated with adverse psychological effects such as
emotional distress, major depressive disorder, panic disorder, and bipolar mania
(Luecken & Compas, 2002). Research shows that psychological stress still remains a
significant problem for cancer patients, their family members, and care givers (Adler &
Page, 2008; Abrahamson et a1. 2011). A greater level of stress is found to be associated
with a greater severity of the disease (Schag et al. 1993). According to some researchers
(Abrahamson et a1. 2011; Jacobsen 2010), nearly 35-45% of cancer patients in the United
States report significant stress. Furthermore, it has been suggested (Abrahamson et a1.
2011; Abrahamson 2010) that this number is most likely an underestimation. Also,
psychological stress is not only being under diagnosed., but is also poorly managed by the
United States health system (Abrahamson et a1. 2011; Jacobsen 2010). Although the
National Comprehensive Cancer Network recommends' routine screening for distress
upon admission and the critical points in the disease process, these guidelines are not
consistently implemented in hospitals. This that being said, this study highlights the
necessity to pay more attention to the psychosocial needs of cancer patients not only due
to the unmet patients' psychosocial needs, but also due to the possible effect that chronic
stress may have on tumor progression.
Stress hormones have been shown not only able to influence tumor progression, but
also may lead to chemoresistance of certain agents. For example., Flint et al. (2009)
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reported that cortisoL, norepinephrine and epinephrine induced drug resistance to a widely
used chemotherapeutic agent., paclitaxel in MDA-MB-231

cells. These findings

emphasize the translational value of the stress hormones in cancer care.
Furthennore, the data generated from this thesis not only identify specific proteins.,
such as MUC 1, and a glucocorticoid pathway that may link psychological stress to tumor
progression, but it also indicates that targeting the neuroendocrine system may be a way
forward in the development of new strategies for reducing psychological stress among
cancer patients. If more in depth studies confirm that the increase in the tumor marker,
MUCl, is caused by elevated levels of stress hormones, antibodies, such as the
huHMFG 1, used for this thesis work, could be administered to patients in the clinic in an
attempt to block the ability of MUC 1 to enhance tumor progression and metastasis.
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generated from two independent
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p < 0.05 compared to controls; error bars represent standard error
of the mean
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